Organ failure – Page 2 – Communicable Diseases Research

IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity

Article

Published on 2022-08-262022-11-15
Journal: The Journal of Infectious Diseases [Category] SARS, 진단,

High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis

COVID-19의 높은 수준의 Von Willebrand 요인 마커: 체계적인 검토 및 메타 분석

Review

Published on 2022-08-012022-09-11
Journal: Clinical and experimental medicine [Category] MERS, SARS, 바이오마커,

Phenotypic Heterogeneity of Fulminant COVID-19–Related Myocarditis in Adults

전격성 COVID-19의 표현형 이질성-성인의 심근염 관련

Article

Published on 2022-07-262022-09-12
Journal: Journal of the American College of Cardiology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술,

[키워드] age autoantibody Characteristics characterized circulating Clinical outcome Clinical presentations COVID-19 COVID-19 symptom criteria Cytokines develop Ejection fraction extracorporeal membrane oxygenation fulminant fulminant myocarditis ICU ICU admission IFN-α2 IL-17 IL-8 immunological infected with SARS-CoV-2 Inflammatory intensive care male management mechanical ventilation Mortality Multisystem inflammatory syndrome myocarditis Organ failure pathophysiology Patient patients phenotype profiles Prognosis renal replacement therapy required Retrospective analysis RNA polymerase RNA polymerase III autoantibodies SARS-CoV-2 Support syndrome TNF-α Treatment tumor necrosis factor-α VA-ECMO ventricular
[DOI] 10.1016/j.jacc.2022.04.056 PMC 바로가기 [Article Type] Article

Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis

Research

Published on 2022-07-212022-10-05
Journal: Nature Medicine [Category] 임상,

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Clinical Trial

Published on 2022-07-082022-10-05
Journal: The Lancet. Respiratory Medicine [Category] 임상, 진단, 치료법,

[키워드] 1:1 addition adverse event Analysis assigned baseline Cohort Complete COVID-19 cumulative defined double-blind Europe extracorporeal membrane oxygenation finding Follow-up funding hazard ratio hospital discharge hospitalised hypothesised IMPROVE incidence infused intravenous Invasive mechanical ventilation investigators modified intention-to-treat monoclonal antibody combination Mortality neutralising NIH occurred operation Organ failure outcome participant Patient Phase 3 phase 3 trial Placebo placebo group placebo-controlled trial Primary outcome randomised Randomly receive receiving Registered Remdesivir renal replacement therapy Result Safe seronegative Singapore speed standard care study drug Study participants Support sustained Symptom the placebo group therapy Treatment Uganda USA were excluded with COVID-19
[DOI] 10.1016/S2213-2600(22)00215-6 [Article Type] Clinical Trial

Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial

Randomized Controlled Trial

Published on 2022-07-012022-10-04
Journal: Intensive care medicine [Category] COVID19(2023년), SARS, 임상,

[키워드] active smoker Acute respiratory failure Administered Adverse affected artificial assessment assigned Care conducted confidence interval coronavirus disease COVID-19 Critically ill patient daily dose days alive dose double-blind Efficacy and safety event France function intensive care unit intensive care units Invasive mechanical ventilation IQR mechanical ventilation median men Mortality multicentre Nicotine Nicotinic receptor not differ Odds ratio on mechanical ventilation Organ failure Patient Placebo placebo-controlled placebo-controlled trial Pneumonia Primary outcome Randomized randomized trial Randomly receive receiving reduce renal replacement therapy secondary outcome Severe COVID-19 pneumonia significantly smoker stratified symptomatic patient the median the placebo group Trial two group two groups vasopressor support Ventilation ventilator-free day with COVID-19
[DOI] 10.1007/s00134-022-06721-1 PMC 바로가기 [Article Type] Randomized Controlled Trial

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

COVID-19 치료에 이중 케모카인 수용체 CCR2/CCR5 억제제 세니크리비록을 사용하는 이유

Review

Published on 2022-06-242022-09-11
Journal: PLoS Pathogens [Category] COVID19(2023년), SARS, 치료제,

[키워드] acute respiratory syndrome coronavirus addition agent anti-inflammatory action anti-inflammatory actions attenuate caused CCR2 CCR5 Cenicriviroc Chemokine receptor clinical Clinical course clinical trial clinical trials Combination complications coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 Dexamethasone fibrosis global pandemic IMPROVE infecting Inflammation inhibitor investigational agent late stage NASH nonalcoholic steatohepatitis Organ failure outcome outcomes pathway Pathways patients with COVID-19 patients with HIV Prevent rationale reduce respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease Standard of care steatohepatitis the disease Treatment Trial
[DOI] 10.1371/journal.ppat.1010547 PMC 바로가기 [Article Type] Review

Symptomatic, clinical and biomarker associations for mortality in hospitalized COVID-19 patients enriched for African Americans

아프리카계 미국인을 위한 입원 COVID-19 환자의 사망률에 대한 증상, 임상 및 바이오마커 연관성

Article

Published on 2022-06-172022-09-11
Journal: BMC Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단,

[키워드] African African American African Americans age American Analysis analyzed Asian association AST Biomarker Cancer cardiac disease Cohort collected Comorbidities Comorbidity COPD correlated COVID-19 creatinine CRP D-dimer death demographics determine diabetes Diabetes Mellitus diarrhea disease severity elevated elevated liver enzymes Ethnicity European fatigue ferritin focus Frequency Gender Glucocorticoids high mortality Hispanic hospital Hospitalized hospitalized COVID-19 patient hospitalized COVID-19 patients hypertension Immunosuppression increased risk Inflammatory biomarker laboratory data large cohort LAT Latinx liver enzyme liver enzymes Lymphocytes male Male sex mechanical ventilation Mortality mortality rates Multivariate analysis New York non-survivor Older age organ Organ failure outcome outcomes Patient patients hospitalized predictor Prevent procalcitonin progression race required SARS CoV-2 SARS-CoV-2 Sex Shortness of breath significant variable significant variables significantly study population subsequent Symptom troponin
[DOI] 10.1186/s12879-022-07520-1 PMC 바로가기 [Article Type] Article

Posterior reversible encephalopathy syndrome – A pathology that should not be overlooked in the era of COVID-19

후두 가역성 뇌병증 증후군 - 코로나19 시대에 간과해서는 안 될 병리학

Case Reports

Published on 2022-06-012022-09-11
Journal: The American journal of emergency medicine [Category] COVID19(2023년), SARS, 변종,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Antibiotics Aphasia Autoimmune diseases blindness Case report cause Computed tomography coronavirus coronavirus disease Coronavirus disease 2019 cortical cortical blindness Corticosteroid Corticosteroids cough COVID-19 delta variant Department described determine diagnosed with COVID-19 Diagnosis dominant drugs Dyspnea eclampsia Emergency emergency department Encephalopathy Europe exhibiting exposure to Fever full recovery general practitioner generalized tonic-clonic seizures had no hypertensive Immediate Infectious disease Infectious diseases Invasion knowledge lobes material medical history MRI nervous system neurological Neurological complication Neurological complications Neurological symptom Neurological symptoms occipital Organ failure outcome pathology Patient patients with COVID-19 Pneumonia Posterior Posterior reversible encephalopathy syndrome PRES presenting radiological receiving renal resolved SARS-CoV-2 SARS-CoV-2 pneumonia secondary to Seizures Sepsis severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe SARS Shortness of breath Symptom syndrome Thoracic Treatment variant
[DOI] 10.1016/j.ajem.2022.03.005 PMC 바로가기 [Article Type] Case Reports

The effect of prostacyclin infusion on markers of endothelial activation and damage in mechanically ventilated patients with SARS-CoV-2 infection

SARS-CoV-2 감염이 있는 기계 환기 환자의 내피 활성화 및 손상 마커에 대한 프로스타사이클린 주입의 효과

Randomized Controlled Trial

Published on 2022-06-012022-09-11
Journal: Journal of critical care [Category] COVID19(2023년), SARS, 바이오마커, 임상,

[키워드] Activation Adult patients baseline Biomarker Biomarkers blood sample Blood samples CD40L change changes in collected COVID-19 damage decrease endothelial Endothelium glycocalyx groups marker mechanically ventilated mechanically ventilated patient mechanically ventilated patients median medians not differ Organ failure P-selectin Patient pilot study Placebo placebo group plasma Plasma levels prostacyclin protective effect Randomized Randomized controlled trial reduction in SARS-CoV-2 SARS-COV-2 infection selectin significantly syndecan Syndecan-1 the placebo group thrombomodulin with COVID-19
[DOI] 10.1016/j.jcrc.2022.154010 PMC 바로가기 [Article Type] Randomized Controlled Trial